Jeevyog

Jeevyog

Zydus Lifesciences Ltd. (Zyduslife) My Stock View and Opinion: Q3 FY25 net profit up 30% YoY to ₹1,023.5 crore. Revenue up 17% YoY. Strategic Moves: Agreement with CVS Caremark to add Zituvio and combination products to its formulary. Product Pipeline: Building a niche product pipeline in the US generics market.

Jeevyog

Highest OPM% in Dec Quarter and stocks CMP is less than its Intrinsic value. Right time to accumulate more for long position upto 60% price growth ahead.